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CI = 40.7–59.5 million), resulted in a statin prescription repre-
senting 24%, and 22%, of the total visits for the two conditions
respectively. Patients aged 41–60 years (OR = 3.49, 95%
CI = 1.43–8.47) or 61–80 years (OR = 3.98, 95% CI = 1.40–
11.31), or those from metropolitan areas (OR: 2.23, 95% CI:
1.11–4.48) were more likely to receive a statin prescription
compared to the respective baseline groups. Whereas residing in
the northeast (OR = 0.44, 95% CI = 0.26–0.75) or midwest
(OR = 0.40, 95% CI = 0.21–0.77) regions or being black
(OR = 0.50, 95% CI = 0.29–0.87) predict signiﬁcantly lower
odds of receiving statin prescription compared with the south
region and nonhispanic whites or other race groups. CONCLU-
SION: As expected, age was the most important factor determin-
ing the prescribing of statins in hypertension and/or diabetes. It is
not clear if these rates of statin prescribing reﬂect aggressive
off-label prescribing or undercoding of on-label diagnoses. Data
on more years needs to be analyzed to conﬁrm the ﬁndings.
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OBJECTIVE: To investigate the trend of ambulatory calcium
channel blockers (CCBs) utilization in Taiwan according to the
national health insurance claims over an eight-year period.
Special attention would be paid to the extent and situations of
prescribing ﬁrst-line (short-acting) CCBs on a PRN (pro re nata)
order. METHODS: The visit-based sampling claims datasets
of ambulatory care visits from 1997 to 2004, offered by the
National Health Insurance Research Database, were analyzed.
The datasets represented 0.2% of total ambulatory care visits
within the National Health Insurance in Taiwan. The utilization
of CCBs was stratiﬁed by ingredient and formulation, and the
prescriptions of CCBs on a PRN order by the patient’s age, the
prescribing physician’s specialty, and the setting of health care
facility. RESULTS: During the study period, the CCBs had
remained as the most popular antihypertensive agents in Taiwan.
The number of deﬁned daily doses (DDDs) of all CCBs per 1000
inhabitants per day increased from 15.3 in 1997 to 36.4 in 2004.
The growth of CCBs was attributed to second- and third-
generation CCBs, especially amlodipine. While the ﬁrst-line
CCBs, mainly short-acting nifedipine, became less popular with
time (from 6.0 DDDs per 1000 inhabitants per day in 1997 to
3.5 in 2004), their PRN use did not have a diminishing trend. In
2004, the short-acting nifedipine on a PRN order still existed in
1.5% of prescriptions containing antihypertensive agents and
3.4% of prescriptions containing CCBs. More than one half of
these PRN orders were prescribed by the internists and to the
elderly patients; almost four-ﬁfths of these PRN orders were
prescribed during normal consultations. CONCLUSION: The
physicians in Taiwan still had the habit of prescribing short-
acting CCBs both on regular use and on PRN use. The reason
for such practices and the impact on patients’ health deserve
attention.
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OBJECTIVE: This study examined associations between pre and
post stroke statin use with health care costs among elderly stroke
survivors enrolled in a Medicare Health Maintenance Organiza-
tion (HMO). METHODS: This was a retrospective analysis of
Medicare HMO in the southeastern region of United States.
Stroke survivors were identiﬁed using primary inpatient dis-
charge codes of 434.xx or 436.xx during the ‘enrollment period’
from January 1, 2000 to December 31, 2002. Patients were
required to have at least 2 prescription ﬁlls for HMG-CoA reduc-
tase inhibitors (statin) and continuous eligibility to the HMO
beneﬁts during index period. Medication adherence was calcu-
lated using prescription reﬁlls. Multivariate log-linear regression
analyses were used to determine predictors of health care costs.
RESULTS: A total 181 stroke patients with mean age of 74.3
years (SD = 7.6) and over 60% were studied. Over 55.2%
patients were on atorvastatin, followed by simvastatin with
24.3%. The average medication possession ratio for statins
was 49.6%. Patients reported poor health status and signiﬁcant
comorbidity. In multivariate log-linear regression analyses
factors, we found that statin use in the year prior to stroke (27%
of the patients) was signiﬁcantly associated with decreased health
care costs (p < 0.05). The only other factor signiﬁcantly associ-
ated with increased health care costs in the post-stroke year
was increased comorbidity severity (p < 0.001). CONCLUSION:
Statin use in elderly HMO enrolled elderly patients in the pre-
stroke period was signiﬁcantly associated with signiﬁcant reduc-
tions in health care utilization and costs in the post-stroke year.
Prophylactic statin use in elderly patients at risk for stroke may
be warranted to decrease post-stroke morbidity resulting in sig-
niﬁcant health care costs.
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OBJECTIVE: To estimate and compare annual medical expen-
ditures and utilization attributed to hypertension in men and
women of the U.S. And to investigate predisposing, enabling and
need predictors of gender differences in hypertension attribut-
able medical expenditures and utilization. METHODS: Proce-
dural equity was assessed by applying the theoretical framework
developed by Aday et.al. We used the 2001–2004 Medical
Expenditure Panel Survey (MEPS) and regression models to esti-
mate medical expenditures and utilization. A cross-sectional
study design was used and unit of analysis was person-year. The
interaction between hypertension and gender was used to study
gender differences. We estimated incremental health care utiliza-
tions attributed to hypertension as difference in utilization and
expenditures between hypertensive and non-hypertensive indi-
viduals. Percentage changes in total and attributable utilization
and expenditures of hypertensive men relative to hypertensive
women were also estimated. RESULTS: Weighted mean total
medical expenditure for hypertensive women and men was
$5512 and $5266 respectively. However, total expenditure
attributable to hypertension for hypertensive women and men
was $3272 and $3910 respectively. Therefore, hypertensive men
had 19.5% more attributable expenditures relative to hyperten-
sive women. Hypertensive women had signiﬁcantly more ofﬁce
visits, prescription drug and outpatient visits. However, similar
to total expenditure, hypertensive men had 27.3% more ofﬁce
visits, 2.9% more prescription drug, and 10.9% more outpatient
visits that is attributable to hypertension than hypertensive
women. CONCLUSION: Gender remained signiﬁcant predictor
of resource use even after controlling for predisposing, enabling
and need factors. Hypertensive women had more utilization and
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expenditures than hypertensive men. However, hypertensive men
had more utilization and expenditures attributed to hypertension
than hypertensive women. Hypertensive men and women with
similar health status and comorbid conditions did not have
similar utilization and expenditures regardless of their age,
income or insurance status. Thus, according to procedural
equity, hypertensive men and women were not being treated
equally.
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OBJECTIVE: To assess the inﬂuence of prescription drug cover-
age on physician recommendations for hypercholesterolemia
treatment, speciﬁcally comparing coverage types that employ
patient copayments and formulary restrictions with unrestricted
coverage. METHODS: Respondents from an ongoing web-based
survey of 2200 randomly-selected primary care physicians in
Florida, Massachusetts, North Carolina and Texas viewed a clini-
cal vignette of a patient with hypercholesterolemia and provided a
treatment recommendation. Insurance was randomly assigned as
commercial, Medicare Part D, Medicaid, or Medicare-Medicaid
dual eligible. Commercial insurance patients had no copayments
or formulary restrictions; other patients’ copayment and formu-
lary information depended on insurance type. We compared drug
choices across insurance groups using chi-square tests and root
mean squared deviations (RMSDs). RESULTS: Data from 229
respondents (1942 eligible, 11.8% response rate)were available at
time of submission; 53 respondents were randomized to patients
with commercial insurance, 59 to Part D, 59 to Medicaid, and 58
to dual eligible. Nearly all physicians (98%) recommended a
statin. Respondents were more likely to select a brand drug for
commercial insurance patients (66%) than for Medicare 22%),
Medicaid (37%), or dual eligible (29%, overall P < 0.001)
patients. The most-prescribed brand agent (atorvastatin) was
recommended more often and the most-prescribed generic agent
(simvastatin) was recommended less often for commercial insur-
ance patients (47%, 30% respectively) than for Medicare (8%,
61%), Medicaid (17%, 51%), and dual eligible (21%, 64%)
patients (overall P < 0.001). Drug choices for the Medicaid group
(RMSD 13.2) most closely approximated the commercial insur-
ance group’s distribution, followed by the dual-eligible (RMSD
15.8) and the Medicare (RMSD 17.8) groups. CONCLUSION:
These preliminary data indicate that physicians’ drug recommen-
dations for hypercholesterolemia treatment differ by patients’
insurance type. In particular, physicians recommended generic
drugsmore often than brand drugs for patientswith drug coverage
that uses copayments and formulary restrictions than for patients
with unrestricted drug coverage.
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OBJECTIVES: One recent analysis of brand to generic switching
patterns in a large, nationally representative pharmacy claims
database from January 2005 to June 2006 suggested that 3% of
patients taking atorvastatin were switched to simvastatin.
However, 38% of these switches were to less potent doses. This
analysis sought to assess the long-term impact of this switching
pattern in the US. METHODS: A Markov model simulated the
future cardiovascular health of Americans aged 35–74 years who
were initially free of cardiovascular disease (CVD), but who met
NCEP-ATPIII criteria for lipid-lowering treatment. Follow-up
occurred until age 75 years. Decision analysis was used to
compare the effects of prescribing all subjects atorvastatin versus
prescribing 97% atorvastatin and 3% simvastatin. Subjects were
proﬁled on participants of the 1999–2004 NHANES. The risks of
CVDand deathwere estimated from application of a Framingham
risk equation and derived from US mortality statistics, respec-
tively. The costs of CVD and statins were derived from adminis-
trative health care claims data. A uniform 3% annual discount
rate was applied. RESULTS: The analysis estimated a cohort of
24,037,997 Americans. If all were to be prescribed atorvastatin,
24.0% would be expected to suffer a cardiovascular event and
24.2% to die by age 75. If 3% were to be prescribed simvastatin
at the observed pattern, the equivalent ﬁgures would be 24.1%
and 24.3%, representing an excess of 2317 cardiovascular events
and 9987 deaths, respectively. There would be a net cost saving
associated with the switch, but at $42,400 per year of life lost and
$27,700 per QALY lost. CONCLUSIONS: In the US, many
patients are being inappropriately switched from atorvastatin to
generic simvastatin, which might lead to an increase in cardiovas-
cular events and overall mortality for little health-economic gain.
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OBJECTIVE: To estimate and compare lifetime (LT) medical
expenditure of hypertension among men and women of the
United States. METHODS: We estimated medical expenditures
with cross-sectional data and survival with prospective data, to
estimate lifetime expenditures from ages 20 to 85+. The 2001–
2004 Medical Expenditure Panel Survey (MEPS) were used to
estimate average annual medical expenditures. Total medical
expenditure was deﬁned as sum of inpatient stay, emergency
room visits, outpatient visits, ofﬁce based visits, and prescription
drugs expenditures. The 1986–2000 National Health Interview
Surveys (NHIS) were linked to mortality in the National Death
Index through 2002, to estimate survival with discrete time
hazard models. A discount rate of 3% was used to estimate the
LT medical expenditures. We controlled for hypertension status,
gender, age and race and ethnicity while estimating regression
models. In addition, interactions between hypertension and other
independent variables were controlled to differentiate different
levels of medical expenditures and mortality between hyperten-
sive and non-hypertensive individuals. Both total and hyperten-
sion attributable expenditures were estimated. RESULTS:
Expected total LT expenditure for individuals at age 20, was
$244,303 for hypertensive men and $259,499 for hypertensive
women. But the LT expenditure that could be attributed to
hypertension was $133,933 for men and $74,088 for women.
Therefore, hypertensive men had about 81% more attributable
LT expenditure relative to hypertensive women. Similarly, hyper-
tensive men of age 40 had about 88% more attributable LT
expenditure than hypertensive women, and hypertensive men of
age 60 had about 93% more attributable LT expenditure relative
to hypertensive women. CONCLUSION: Although hypertensive
women have more expected LT total expenditure than men,
hypertensive men had relatively more expected LT attributable
expenditure than women at different ages and the gap widened
with age.
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